Clinical Trial

A Study of BGB-11417 in Participants With Myeloid Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Protocol Amendment History 1 change
notable Sponsor changed: BeiGene -> BeOne Medicines 2026-07-14
Trial Details
NCT Number NCT04771130
Lead Sponsor BeOne Medicines
Conditions Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
Enrollment 260 participants
Start Date 2021-05-24
Primary Completion 2028-02-08 (estimated)
Study Completion 2028-02-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-13